MedPath

The PRE-OP ENERGY Trial

Not Applicable
Recruiting
Conditions
Coronary Artery Disease
Organ Failure, Multiple
Cardiac Valve Disease
Interventions
Dietary Supplement: High energy diet
Registration Number
NCT04015973
Lead Sponsor
University of Leicester
Brief Summary

The PRE-OP ENERGY Trial proposes to test the overarching hypothesis that a pre-surgery high energy diet will protect patients against organ damage during cardiac surgery with cardiopulmonary bypass.

Detailed Description

PRE-OP ENERGY is a single centre, unblinded, parallel group, randomised controlled trial of a pre-operative high energy diet, versus a control group receiving standard care.

The trial will test a number of specific hypotheses:

1. A pre-surgery high energy diet will protect against post-cardiac surgery organ failure by altering the pre-surgery cardiometabolic state, a process referred to as 'metabolic preconditioning'.

2. The effects of the trial intervention will not be attributable to changes in frailty, activity or baseline organ dysfunction.

3. The trial intervention will not result in long-term adverse changes in cardiometabolic status.

4. Metabolic preconditioning will confer protection against post-cardiac surgery kidney injury by increasing the expression of genes that promote renal tubular homeostasis.

5. Metabolic preconditioning will confer protection against post-cardiac surgery myocardial injury by increasing the expression of genes that promote myocardial mitochondrial homeostasis via effects on chromatin histone deacetylation.

6. Metabolic preconditioning will confer protection against post-cardiac surgery endothelial dysfunction by increasing the expression of genes that promote endothelial homeostasis.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
116
Inclusion Criteria

ALL of the following:

  • Adult cardiac surgery patients (≥18 years) undergoing cardiac surgery (CABG, Valve, or CABG and Valve) with cardiopulmonary bypass.
  • BMI<30
  • Able, in the opinion of the investigator, and willing to give informed consent.
  • Do not have diagnosed coeliac disease
  • Able to understand English
Exclusion Criteria

Any of the following:

  • Urgent, emergency or salvage procedure
  • Patients with end stage renal failure defined as an estimated Glomerular Filtration rate (eGFR) <15 mL/min/1.73 m2 calculated from the Modification of Diet in Renal Disease equation,1 or patients who are on long-term haemodialysis or have undergone renal transplantation.
  • Patients with persistent or chronic atrial fibrillation.
  • Patients with severe liver dysfunction; hepatitis, cirrhosis, jaundice.
  • Women who are pregnant or who may become pregnant in the intraoperative period.
  • Patients who are participating in another interventional clinical trial.
  • Unable, in the opinion of the investigator, or unwilling to give informed consent.
  • Have diagnosed coeliac disease
  • Unable to understand English

Exclusion criteria for optional MRI research procedure:

  • Permanent pacemaker or ICD
  • Brain Aneurysm Clip
  • Implanted neural stimulator
  • Cochlear implant (specific implant must be checked that it is MR safe)
  • Ocular foreign body (e.g. metal shavings) unless removed
  • Other implanted medical devices: (e.g. Swan Ganz catheter)
  • Insulin pump
  • Retained metal shrapnel or bullet
  • Claustrophobia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group B: High energy dietHigh energy dietHigh energy diet for 8-12 weeks pre-surgery
Primary Outcome Measures
NameTimeMethod
Change of Serum Troponin I levelBaseline, 0-6, 6-12, 24, 48 and 72 hours post-operatively

Measurement of Serum Troponin level and expressed as ng/L.

Change of Serum Creatinine levelBaseline, 0-6, 6-12, 24, 48, 72, and up to 96 hours post-operatively

Measurement of Serum Creatinine level and expressed as umol/L.

Secondary Outcome Measures
NameTimeMethod
Post-surgery organ injury: GI Tract injury (Biomarker) - BilirubinBaseline, pre-assessment, pre-operatively, 0-6 and at 6-12, 24, 48, 72 and 96 hours post-operatively.

Measurement of Bilirubin levels in serum and expressed in μmol/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal.

Post-surgery organ injury: Sepsis-related Organ FailureBaseline, pre-operatively, 0-6, 6-12, 24, 48, 72 and 96 hours post-operatively

Sepsis-related Organ Failure Assessment (SOFA) Score. Range 0-3, 3 being the worse score

Post-surgery organ injury: Kidney Injury (Urinary Biomarkers) - NGAL (Neutrophil gelatinase associated lipocalcin)Baseline, 1 day pre-op, 6-12, 24 and 48 hours post-operatively

Urine samples will be analysed for biomarkers of renal injury. Measurement of NGAL level will be expressed as μg/L.

Post-surgery organ injury: GI Tract injury (Biomarker) - Serum AmylaseBaseline, pre-assessment, pre-operatively, 0-6 and at 6-12, 24, 48, 72 and 96 hours post-operatively.

Measurement of Amylase levels in serum and expressed in IU/L. Acute pancreatitis will be defined as a serum amylase concentration \>1000 ng/ml.

Clinical events: StrokeTime (days) measured from the start of surgery to discharge from hospital (up to 90 days)

Stroke; diagnosed by brain imaging (CT or MRI), in association with new onset focal or generalized neurological deficit (defined as deficit in motor, sensory or co-ordination functions)

Clinical events: Rate of mortalityWithin 30-days from surgery and at 1 year from surgery

Rate of mortality at 30-days and 1 year from the date of surgery

Bleeding and TransfusionBlood loss at 6 hours post-operatively

The total number of units of red cells and other blood components transfused during the operative period and post-operative hospital stay will be recorded

Mechanism study: Chromatin Immunoprecipitation (ChIP) of microvessels from tissue biopsiesAt time of surgery

To identify protein binding sites that may help identify functional elements in the genome. Findings will be represented by the number (n) of binding sites. 50-100 mg biopsies obtained from pedicled left internal mammary artery biopsies.

Mechanism study: Mitochondrial function measured in right atrium myocardium tissue biopsiesAt time of surgery

50-100 mg myocardial biopsies will be obtained from the right atrium at surgery. The mitochondrial function will be measured through the Bioenergetic Health Index. The Bioenergetic Health Index (BHI) is calculated using the following formula: BHI=(ATP-linked×reserve capacity)/(proton leak×non-mitochondrial) - as described by Chacko et al. The expected range is 0-100.

Post-surgery organ injury: Lung Injury using the Berlin ARDS ScoreBaseline, immediately pre-surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-operatively

Using the Berlin ARDS score, the measurement of Arterial Alveolar oxygen ratio expressed in kPa/L.

Post-surgery organ injury: GI Tract injury (Biomarker) - Alkaline PhosphataseBaseline, pre-assessment, pre-operatively, 0-6 and at 6-12, 24, 48, 72 and 96 hours post-operatively.

Measurement of Alkaline Phosphatase levels in serum and expressed in IU/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal.

Assessment of resource use: Intensive Care UnitTime (hours) measured from the start of surgery to discharge from ICU (up to 30 days)

Length of stay in Intensive Care Unit. Number of hours between admission and discharge from the High Dependency Unit (HDU)

Assessment of resource use: Hospital StayTime (days) measured from the start of surgery to discharge from hospital (up to 90 days)

Length of stay in hospital. Number of days between admission and discharge from the hospital

Clinical events: Acute Liver Injury - ALT (Alanine Transaminase)Time (days) measured from the start of surgery to discharge from hospital (up to 90 days)

Acute liver injury will be defined as an acute derangement of liver enzymes three times the upper limit of normal, or a serum amylase concentration \>1000 ng/m.

Clinical events: Acute Liver Injury - Serum AmylaseTime (days) measured from the start of surgery to discharge from hospital (up to 90 days)

Acute liver injury will be defined as an acute derangement of liver enzymes three times the upper limit of normal, or a serum amylase concentration \>1000 ng/m.

Mechanism study: Mitochondrial function of microvessels from tissue biopsiesAt time of surgery

50-100 mg biopsies obtained from pedicled left internal mammary artery biopsies. The mitochondrial function will be measured through the Bioenergetic Health Index. The Bioenergetic Health Index (BHI) is calculated using the following formula: BHI=(ATP-linked×reserve capacity)/(proton leak×non-mitochondrial) - as described by Chacko et al. The expected range is 0-100.

Mechanism study: microRNA isolation of microvessels from tissue biopsiesAt time of surgery

The findings will be represented by the frequency (%) of identified microRNA. 50-100 mg biopsies obtained from pedicled left internal mammary artery biopsies.

Mechanism study: Chromatin Immunoprecipitation (ChIP) in right atrium myocardium tissue biopsiesAt time of surgery

50-100 mg myocardial biopsies will be obtained from the right atrium at surgery. To identify protein binding sites that may help identify functional elements in the genome. Findings will be represented by the number (n) of binding sites.

Mechanism study: Chromatin Immunoprecipitation (ChIP) in adipose tissue biopsiesAt time of surgery

Adipose tissue collected from epicardial fat at time of surgery. To identify protein binding sites that may help identify functional elements in the genome. Findings will be represented by the number (n) of binding sites.

Post-surgery organ injury: GI Tract injury (Biomarker) - ALT (Alanine Transaminase)Baseline, pre-assessment, pre-operatively, 0-6 and at 6-12, 24, 48, 72 and 96 hours post-operatively.

Measurement of ALT levels in serum and expressed in IU/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal.

Clinical events: Low cardiac outputTime (days) measured from the start of surgery to discharge from hospital (up to 90 days)

Low cardiac output, defined as new intra-or postoperative intra-aortic balloon pump insertion or a cardiac index of \<2.2 L/min/ m2 refractory to appropriate intravascular volume expansion after correction or attempted correction of any dysrhythmias, or the administration of the inotropes Dobutamine, Enoximone, Milrinone or Levosimendan.

Mechanism study: Measurement of microRNA in urine samplesBaseline,1 day before surgery, 6-12, 24 and 48 hours post-operatively.

The findings will be represented by the frequency (%) of identified microRNA.

Post-surgery organ injury: Kidney Injury (Urinary Biomarkers) - microRNA (Neutrophil gelatinase associated lipocalcin)Baseline, 1 day pre-op, 6-12, 24 and 48 hours post-operatively

Urine samples will be analysed for biomarkers of renal injury. Measurement of microRNA in urine samples will be represented by the frequency (%) of identified microRNA.

Post-surgery organ injury: Kidney InjuryAt 6 weeks and then 3 months post-surgery

Serum creatinine and eGFR in all patients using the Modification of Diet in Renal Disease equation. The following is the IDMS-traceable MDRD Study equation (for creatinine methods calibrated to an IDMS reference method) GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if African American) The equation does not require weight or height variables because the results are reported normalized to 1.73 m2 body surface area, which is an accepted average adult surface area.

Post-surgery organ injury: GI Tract injury (Biomarker) - AST (Aspartate Transaminase)Baseline, pre-assessment, pre-operatively, 0-6 and at 6-12, 24, 48, 72 and 96 hours post-operatively.

Measurement of AST levels in serum and expressed in IU/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal.

Clinical events: SepsisTime (days) measured from the start of surgery to discharge from hospital (up to 90 days)

Sepsis will be defined as suspected or documented infection and an acute change in total SOFA score ≥2 points consequent to the infection. For the purposes of the trial suspected or documented infection will be defined as the commencement of intravenous antibiotics. The rise in SOFA score will be assessed within 72 hours of the commencement of antibiotics. Range of SOFA is 0 to 3, 3 being the worse. For the purposes of the study suspected or documented infection will be defined as the commencement of intravenous antibiotics. The rise in SOFA score will be assessed within 72 hours of the commencement of antibiotics.

Clinical events: Peak lactateWithin 24 hours of surgery

Peak lactate within 24 hours of surgery and time to resolution of hyperlactataemia (arterial serum lactate \>2.5 mmol/L) post peak.

Clinical events: Acute Liver Injury - BilirubinTime (days) measured from the start of surgery to discharge from hospital (up to 90 days)

Acute liver injury will be defined as an acute derangement of liver enzymes three times the upper limit of normal, or a serum amylase concentration \>1000 ng/m.

Mechanism study: microRNA isolation in right atrium myocardium tissue biopsiesAt time of surgery

50-100 mg myocardial biopsies will be obtained from the right atrium at surgery. The findings will be represented by the frequency (%) of identified microRNA.

Assessment of resource use: ExtubationTime (hours) measured from the start of surgery to extubation (up to 30 days)

Time until extubation

Clinical events: Acute Lung InjuryBaseline, immediately pre-surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-operatively

Measurement of PaO2/FiO2 ratio and expressed in kPa/L.

Clinical events: Acute Liver Injury - AST (Aspartate Transaminase)Time (days) measured from the start of surgery to discharge from hospital (up to 90 days)

Acute liver injury will be defined as an acute derangement of liver enzymes three times the upper limit of normal, or a serum amylase concentration \>1000 ng/m.

Clinical events: Acute Liver Injury - Alkaline PhosphataseTime (days) measured from the start of surgery to discharge from hospital (up to 90 days)

Acute liver injury will be defined as an acute derangement of liver enzymes three times the upper limit of normal, or a serum amylase concentration \>1000 ng/m.

Clinical events: Acute Intestinal InjuryTime (days) measured from the start of surgery to discharge from hospital (up to 90 days)

Acute intestinal injury will be defined a radiological, operative or post-mortem evidence of gut ischaemia.

Clinical events: A composite endpoint Organ Injury, Mortality and SepsisTime (days) measured from the start of surgery to discharge from hospital (up to 90 days)

As above for description of organ injury, mortality and sepsis

Mechanism study: microRNA isolation in adipose tissue biopsiesAt time of surgery

Adipose tissue collected from epicardial fat at time of surgery. The findings will be represented by the frequency (%) of identified microRNA.

Mechanism study: Measurement of histone acetylation in urine samplesBaseline,1 day before surgery, 6-12, 24 and 48 hours post-operatively.

The findings will be reported as acetylated H3 (ug/mg) over time (hours)

Mechanism study: Mitochondrial function measured in adipose tissue biopsiesAt time of surgery

Adipose tissue collected from epicardial fat at time of surgery. The mitochondrial function will be measured through the Bioenergetic Health Index. The Bioenergetic Health Index (BHI) is calculated using the following formula: BHI=(ATP-linked×reserve capacity)/(proton leak×non-mitochondrial) - as described by Chacko et al. The expected range is 0-100.

Mechanism study: Measurement of microvesicles in urine samplesBaseline,1 day before surgery, 6-12, 24 and 48 hours post-operatively.

Identification of microvesicles. The findings will be represented by the frequency (%) of each identified microvesicle.

Mechanism study: Measurement of gene expression in urine samplesBaseline,1 day before surgery, 6-12, 24 and 48 hours post-operatively.

Whole genome sequencing will be achieved through ATAC sequencing. The identified genes will be characterised by average expression count over ATAC.

Trial Locations

Locations (1)

University of Leicester

🇬🇧

Leicester, Leicestershire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath